NEW YORK--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) announced data that the company believes supports further development of its drug candidates, INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec resistant or intolerant chronic myelogenous leukemia, and INNO-305, a peptide immunotherapy for the treatment of acute myelogenous leukemia, will be presented at the American Society of Hematology (ASH) 49th Annual Meeting and Exposition. The conference takes place December 8-11, 2007 at the Georgia World Congress Center in Atlanta.
